loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Neuland Laboratories Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Neuland Laboratories Ltd. 07 Nov 2025 16:37 PM
Result PDF

Q2FY26 Quarterly Result Announced for Neuland Laboratories Ltd.

Pharmaceuticals company Neuland Laboratories announced Q2FY26 results

  • Total Income: Rs 516.1 crore compared to Rs 315.2 crore during Q2FY25, change 63.70%.
  • EBITDA: Rs 156.9 crore compared to Rs 65.7 crore during Q2FY25, change 138.80%.
  • EBITDA Margin: 30.40% for Q2FY26.
  • PBT: Rs 129.0 crore compared to Rs 48.5 crore during Q2FY25, change 166.60%.
  • PAT: Rs 96.5 crore compared to Rs 32.0 crore during Q2FY25, change 201.60%.

Sucheth Davuluri, Vice-Chairman & Chief Executive Officer, said: “The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.”

Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.”

Result PDF

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q1FY26 results

  • Total Income: Rs 300.6 crore compared to Rs 444.4 crore during Q1FY25, change -32.40%.
  • EBITDA: Rs 42.1 crore compared to Rs 128.6 crore during Q1FY25, change -67.30%.
  • EBITDA Margin: 14.00% for Q1FY26.
  • PBT: Rs 17.4 crore compared to Rs 130.3 crore during Q1FY25, change -86.80%.
  • PAT: Rs 13.7 crore compared to Rs 98.3 crore during Q1FY25, change -86.10%.

Sucheth Davuluri, Vice-Chairman and Chief Executive Officer, said: “While Q1FY26 has been below par as a result of the flow of customer orders, it doesn’t change our outlook on the healthy growth that we anticipate this financial year. The investments we have announced are proceeding according to plan and would be drivers of short as well as long term growth. We continue to focus on cost optimization opportunities across products and processes which will enable us to further strengthen our position in key products.”

Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “We see substantial growth this year from our commercial molecules even as there is a significant influx of new business from existing and new customers along with customers’ pipeline projects making exciting progress. Given customers’ interest and evolving expectations we are continuing to invest in our people and capabilities which should see Neuland further differentiated as a CDMO with deep expertise as well as an agile innovative partner.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Total Income: Rs 335.8 crore vs. Rs 390.4 crore — down 14.0%
  • EBITDA: Rs 58.2 crore vs. Rs 112.2 crore — down 48.1%
  • EBITDA Margin %: 17.3% vs. 28.7% — contracted by 1140 bps
  • PAT: Rs 27.7 crore vs. Rs 67.6 crore — down 59.0%
  • PAT Margin %: 8.3% vs. 17.3% — contracted by 900 bps
  • EPS (Basic): Rs 21.6 vs. Rs 52.7 — down 59.0%

FY25 Financial Highlights:

  • Total Income: Rs 1,497.3 crore vs. Rs 1,571.1 crore — down 4.7%
  • EBITDA: Rs 342.8 crore vs. Rs 474.5 crore — down 27.7%
  • EBITDA Margin %: 22.9% vs. 30.2% — contracted by 730 bps
  • PAT: Rs 259.4 crore vs. Rs 299.6 crore — down 13.4%
  • PAT Margin %: 17.3% vs. 19.1% — contracted by 180 bps
  • EPS (Basic): Rs 202.2 vs. Rs 233.5 — down 13.4%

Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We saw marginal decrease in topline in FY25 as compared to FY24. which is further reflected in terms of the decline in operating margins. Nevertheless, these results are in line with our initial outlook at the start of the year regarding our expectations for FY25. During the course of the year we have committed to making investments which will significantly drive our growth in the medium and long term. Neuland continues to be recognized for its capabilities and quality track record, and we have good visibility on short and long term growth”

In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “The CMS revenues of Rs. 637 crores were largely driven by molecules in the commercial segment. Even though the revenues have declined this year, we continue to see good traction in business from a wider range of customers Our peptide investment plan is on track. We continue to garner more projects in this space which further validates our excitement about the opportunities that the segment holds. At an overall level, we have molecules in our portfolio which are currently at the take off stage, therefore we expect our growth trajectory to resume in FY26.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q3FY25 results

  • Total Income: Rs 401.9 crore (1.8% growth YoY from Rs 394.9 crore).
  • EBITDA: Rs 90.3 crore (decline of 26.4% YoY from Rs 122.7 crore).
  • EBITDA Margin: 22.5% (decline of 860 bps YoY from 31.1%).
  • PAT: Rs 101.4 crore (growth of 25.6% YoY from Rs 80.7 crore).
  • PAT Margin: 25.2% (increase of 480 bps YoY from 20.4%).
  • EPS (Basic): Rs 79.0 (growth of 25.6% YoY from Rs 62.9).

Sucheth Davuluri, Vice-Chairman & Chief Executive Officer of the Company said: “We saw marginal topline growth this quarter as compared to Q3FY24. Nevertheless, these results align with our initial outlook at the start of the year regarding our expectations for FY25. We are steadily advancing our strategic initiatives and remain optimistic about achieving sustainable long-term growth through acquiring new customers, enhancing our expertise, expanding our capacity flexibly, and refining our processes.”

Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “This quarter’s revenues were driven by several important molecules in the commercial CMS and GDS segments. We expect the recently commercialized molecules to scale even as we are on track to enhance our manufacturing capacity. There is good traction from our existing customers reverting for multiple projects as well as fresh interest from a range of new customeRs We are seeing increased interest in peptides leading to our recent decision to invest in a larger capacity. Overall, we are confident on the business momentum for the medium as well as long term.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Total Income for Q2FY25 at Rs 315.2 crore (-25.1% YoY).
  • EBITDA for Q2FY25 at Rs 65.7 crore (-53.2% YoY).
  • EBITDA Margin for Q2FY25 at 20.8% (decreased by 1260 bps YoY).
  • PAT for Q2FY25 at Rs 32.0 crore (-64.1% YoY)*.
  • Net Debt stood at Rs -94.3 crore as at Q2FY25 end compared to Rs -39.2 crore as at Q2FY24 end and Rs -110.2 crore as at Q1FY25 end.

H1FY25 Financial Highlights:

  • Total Income for H1FY25 at Rs 759.6 crore (-3.3% YoY).
  • EBITDA for H1FY25 at Rs 194.3 crore (-18.9% YoY).
  • EBITDA Margin for H1FY25 at 25.6% (decreased by 490 bps YoY).
  • PAT for H1FY25 at Rs 130.3 crore (-13.9% YoY)*.
  • Net Debt stood at Rs -94.3 crore as at H1FY25 end compared to Rs -39.2 crore as at H1FY24 end.

Sucheth Davuluri: “The numbers of this quarter are subpar relative to how the business has been performing over the last few quarteRs However, they are in line with our commentary right at the beginning of the year as to how we see FY25 panning out. The inherent uneven nature of our business means that annual progression is a better indicator of the company’s prospects than quarterly performance. We continue to make progress on our strategic plans and are enthusiastic about sustainable long-term growth driven by customer acquisitions, deepening capabilities, agile capacity expansion and optimization of processes.”

Saharsh Davuluri: “The revenues this quarter were driven by a few key molecules on the commercial CMS and GDS specialty side. Completion of additional manufacturing facilities in this year coupled with anticipated commercial launch of molecules on the CMS side gives us the confidence of achieving high growth in FY26 and beyond. We believe that the environment remains favourable for us in the medium to long term as indicated by customer interest and addition of early-stage projects.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q1FY25 results:

  • Total Income: Rs 444.4 crore, reflecting a YoY growth of 21.7% compared to Q1FY24 (Rs 365.0 crore) and a QoQ growth of 13.8% from Q4FY24 (Rs 390.4 crore).
  • EBITDA: Rs 128.6 crore, representing a 29.5% increase from Q1FY24 (Rs 99.3 crore) and a 14.7% rise from Q4FY24 (Rs 112.2 crore).
  • EBITDA Margin: 28.9%, an increase of 174 basis points from Q1FY24 (27.2%) and a slight increase of 21 basis points from Q4FY24 (28.7%).
  • Exceptional Item: Rs 20.6 crore (noted for the quarter).
  • Profit After Tax (PAT): Rs 98.3 crore, up 58.0% from Q1FY24 (Rs 62.2 crore) and a 45.5% increase from Q4FY24 (Rs 67.6 crore).
  • PAT Margin: 22.1%, a growth of 510 basis points compared to Q1FY24 (17.0%) and up 480 basis points from Q4FY24 (17.3%).
  • Earnings Per Share (EPS): Rs 76.6, reflecting a 58.0% increase from Q1FY24 (Rs 48.5) and a 45.5% rise from Q4FY24 (Rs 52.7).

Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We recorded our highest ever quarterly revenues in Q1FY25 led by growth in the CMS business even as we recorded healthy EBITDA margins. We continue to maintain that FY25 will be a year of normalisation of revenue growth and subsequently margins as we continue to invest for growth. We expect our business to regain momentum from FY26 onwards basis our visibility from our portfolio of projects and products.”

In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “The CMS revenues were driven by commercial molecules in line with our expectations as we outline our strategy over the years. As we evaluate our pipeline of projects and the flow of new projects, we remain enthusiastic on the strong potential of the CMS business over the long term. The GDS business continues to build on the strong base we have with quality focussed customers, even as our R&D team is working on an exciting set of molecules to add to our portfolio.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q4FY24 & FY24 results:

  • FY24 income at Rs 1,571.1 crore, up 30.8% YoY
  • EBITDA at Rs 474.5 crore, up 68.8% YoY

Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We surpassed revenues of Rs 1,500 crore in FY24 with EBITDA at over 30%. This has been driven by high growth in the CMS business and steady growth of the Specialty GDS business, both of which were in line with our plans and expectations. Another key element is the work on optimizing costs & processes which will also make us truly sustainable.”

In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw robust growth in FY24 as some projects are near launch while key commercial products continue to scale. Our growing reputation and the macro-environment are ensuring that exciting opportunities come our way even as we work towards building a further differentiated customer experience. We will continue to invest for the future by adding capacity and capabilities.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q3FY24 & 9MFY24 results:

Q3FY24 vs Q4FY23:

  • Total Income: Rs 394.9 crore, showing a growth of 46.2% compared to Q3FY23.
  • EBITDA: Rs 122.7 crore, increased significantly by 123.5% from Q3FY23.
  • EBITDA Margin: 31.1%, improved by 1080 basis points (bps) from Q3FY23.
  • PAT: Rs 80.7 crore, showing a substantial growth of 165.1% compared to Q3FY23.
  • PAT Margin: 20.4%, increased by 910 bps from Q3FY23.
  • EPS (Basic): Rs 62.9, reflecting a growth of 165.1% compared to Q3FY23.

9MFY24 vs 9MFY23:

  • Total Income: Rs 1,180.8 crore, increased significantly by 50.3% compared to 9MFY23.
  • EBITDA: Rs 362.3 crore, showing a substantial growth of 136.4% compared to 9MFY23.
  • EBITDA Margin: 30.7%, improved by 1120 bps from 9MFY23.
  • PAT: Rs 232.0 crore, showing a substantial growth of 195.1% compared to 9MFY23.
  • PAT Margin: 19.6%, increased by 960 bps from 9MFY23.
  • EPS (Basic): Rs 180.8, reflecting a growth of 195.1% compared to 9MFY23.

Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We are pleased to report another quarter of strong YoY topline growth of 46% to Rs 395 crore. The EBITDA margin of 31.1% is a factor of the business mix as well as improved operational leverage. Even as we see this as a validation of Neuland’s business model, we are focused on continuously improving operations across the company. We are investing both on infrastructure and our people so that we can deliver on our long-term plans.”

In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw healthy growth led by commercial as well as projects close to commercialization. The increasing interest from customers with exciting pipelines establishes Neuland’s reputation as a well regarded CDMO. As the quality and size of our business grows, we are gaining a better visibility of our future and planning accordingly.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q1FY24 results:

  • Total Income of Rs 365.0 crore in Q1FY24 compared to Rs 221.7 crore in Q1FY23, up 64.7% YoY
  • EBITDA of Rs 99.3 crore in Q1FY24 compared to Rs 29.0 crore in Q1FY23, up 242.5% YoY
  • EBITDA margin of 27.2% in Q1FY24 compared to 13.1% in Q1FY23 , up 1,410 bps YoY
  • PAT of Rs 62.2 crore in Q1FY24 compared to Rs 9.8 crore in Q1FY23, up 532.3% YoY
  • PAT margin of 17.0% in Q1FY24 compared to Rs 4.4% in Q1FY23, up 1,260 bps YoY
  • EPS (Basic) of Rs 48.5 in Q1FY24 compared to Rs 7.7 in Q1FY23, up 532.3% YoY

Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “The performance this quarter is in line with our plan and is a good indicator of the business momentum within the organization. The high YoY growth had contributions from all three segments and the EBITDA margin improvement of 1,410 bps on a YoY basis reflects the change in business mix as well as operating leverage playing out. We continue to be watchful on balancing growth with profitability by having a continuous focus on cost optimization and efficient operations to capitalise on opportunities which we believe will bring us greater scale over the long term.”

In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added, “CMS growth in Q1FY24 was driven by recently commercialized molecules as well as molecules in the pipeline. We expect more molecules to be commercialized in the medium term which will drive our future growth. We saw a couple of more milestones in terms of our regulatory track record as Unit 3 was successfully inspected by the US FDA and we had Unit-1 being audited by EDQM. While the external environment remains uncertain with funding of early-stage molecules being affected, we remain cautiously optimistic about our future growth given the strength of our portfolio.”

 

 

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Total Income for Q4FY23 at Rs 415.1 crore ( 61.8% YoY) led by growth in Specialty and CMS segment
    • EBITDA for Q4FY23 at Rs 127.8 crore ( 224.8% YoY)
    • EBITDA Margin for Q4FY23 at 30.8% (increased by 1550 bps YoY)
    • PAT for Q4FY23 at Rs 84.5 crore ( 287.2% YoY)
    • Net Debt stood at Rs 63.0 crore as at Q4FY23 end compared to Rs 212.0 crores as at Q4FY22 end and Rs 72.0 crores as at Q3FY23 end
  • FY23:
    • Total Income for FY23 at Rs 1,200.9 crore ( 26.0% YoY) led by growth in Specialty and CMS segment
    • EBITDA for FY23 at Rs 281.1 crore ( 94.8% YoY)
    • EBITDA Margin for FY23 at 23.4% (increased by 830 bps YoY) due to a better business mix
    • PAT for FY23 at Rs 163.1 crore ( 156.7% YoY) due to a slower increase in depreciation compared to an increase in EBITDA
    • Debt/Equity stood at 0.12x due to the retirement of Rs 113.6 crore borrowings (net) in FY23
    • Net Debt stood at Rs 63.0 crore as at FY23 end compared to Rs 212.0 crore as at FY22 end

Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We crossed several significant milestones in FY23 with business driven by ongoing growth in the high margin Specialty and CMS business. The performance of this fiscal reflects the various initiatives we have taken in line with our strategy over the last few years, playing out now. We believe that this puts us in a strong position as we look to consolidate the healthy momentum going forward.”

In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added “We are happy to state that our focus on R&D and project management saw us achieve our highest ever profitability margins in FY23. We executed a number of CMS projects during the year resulting in the business recording significant growth and contributing close to half the Q4 revenues. We expect this momentum to continue in the future as well on account of new customers increasingly accepting Neuland as an established CDMO.”

 

 

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status